Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bin Lan

Showing results (171-180 of 173) with videos related to

Pageof 18
Sort By:
You have reached the last page of results.This site can display upto 173 results.
Cell Death Discovery|March 9, 2024
Roflumilast inhibits tumor growth and migration in STK11/LKB1 deficient pancreatic cancerShuman Zhang, Duo Yun, Hao Yang, et al.
Signal Transduction and Targeted Therapy|August 12, 2024
Gefitinib (an EGFR tyrosine kinase inhibitor) plus anlotinib (an multikinase inhibitor) for untreated, EGFR-mutated, advanced non-small cell lung cancer (FL-ALTER): a multicenter phase III trialHua-Qiang Zhou, Ya-Xiong Zhang, Gang Chen, et al.
Cell Research|September 19, 2023
Low glucose metabolite 3-phosphoglycerate switches PHGDH from serine synthesis to p53 activation to control cell fateYu-Qing Wu, Chen-Song Zhang, Jinye Xiong, et al.
Pageof 18

Showing results (171-180 of 173) with videos related to

Sort By:
Pageof 18
You have reached the last page of results.This site can display upto 173 results.
Cell Death Discovery|March 9, 2024
Roflumilast inhibits tumor growth and migration in STK11/LKB1 deficient pancreatic cancerShuman Zhang, Duo Yun, Hao Yang, et al.
Signal Transduction and Targeted Therapy|August 12, 2024
Gefitinib (an EGFR tyrosine kinase inhibitor) plus anlotinib (an multikinase inhibitor) for untreated, EGFR-mutated, advanced non-small cell lung cancer (FL-ALTER): a multicenter phase III trialHua-Qiang Zhou, Ya-Xiong Zhang, Gang Chen, et al.
Cell Research|September 19, 2023
Low glucose metabolite 3-phosphoglycerate switches PHGDH from serine synthesis to p53 activation to control cell fateYu-Qing Wu, Chen-Song Zhang, Jinye Xiong, et al.
Pageof 18